The study of sugars in biology, called glycobiology, is a growing field of research. This is partly due to the increased understanding of the major role sugars play in many diseases, including cancer. To better understand the biology of these sugars and as a starting point for the development of new medicines, we developed substances that can lower the presentation of sugars on cells in the body.
Johan Pijnenborg obtained his master's degree in chemistry cum laude at Radboud University in Nijmegen. In 2018 he started his PhD in chemical glycobiology. He is now committed to the valorization of developed compounds with his companies Synvenio & GlycoTherapeutics.